InvestmentOct 1, 2026, 03:56 PM
Mangoceuticals Subsidiary Secures $2.5M Investment in IP
AI Summary
Mangoceuticals, Inc. announced that its wholly-owned subsidiary, MangoRx IP Holdings, LLC, has entered into subscription agreements with two accredited investors for an aggregate investment of $2.5 million directly into MangoRx IP. The company has received an initial tranche of $1.75 million, representing a 17.5% membership interest, with the remaining $750,000 due within 60 days for an additional 7.5% interest. This subsidiary-level investment will not result in the issuance of any Mangoceuticals common stock, thereby preserving the parent company's capitalization structure. The funds are intended to advance the commercialization of MangoRx IP's antiviral technology portfolio, MGX-0024.
Key Highlights
- Mangoceuticals' subsidiary, MangoRx IP Holdings, secured $2.5 million in investment.
- Two accredited investors purchased an aggregate 25% membership interest in MangoRx IP.
- Initial tranche of $1.75 million received, representing a 17.5% interest.
- Second tranche of $750,000 due within 60 days for the remaining 7.5% interest.
- Investment is at the subsidiary level, no MGRX common stock issued, preserving parent capitalization.
- Proceeds will advance commercialization of the Company's antiviral intellectual property portfolio (MGX-0024).
Price Impact
More from MGRX